ACP-ESM: A novel framework for classification of anticancer peptides using protein-oriented transformer approach

TL;DR

This paper introduces ACP-ESM, a transformer-based framework that significantly improves the accuracy of anticancer peptide classification, achieving state-of-the-art results across multiple datasets using protein-oriented transformer models.

Contribution

The paper presents a novel transformer-based framework employing four different models to accurately predict anticancer peptides, setting new benchmarks in classification performance.

Findings

ESM model achieved 96.45% accuracy on AntiCp2 dataset

Model outperformed existing methods on multiple datasets

Proposed framework enhances peptide classification reliability

Abstract

Anticancer peptides (ACPs) are a class of molecules that have gained significant attention in the field of cancer research and therapy. ACPs are short chains of amino acids, the building blocks of proteins, and they possess the ability to selectively target and kill cancer cells. One of the key advantages of ACPs is their ability to selectively target cancer cells while sparing healthy cells to a greater extent. This selectivity is often attributed to differences in the surface properties of cancer cells compared to normal cells. That is why ACPs are being investigated as potential candidates for cancer therapy. ACPs may be used alone or in combination with other treatment modalities like chemotherapy and radiation therapy. While ACPs hold promise as a novel approach to cancer treatment, there are challenges to overcome, including optimizing their stability, improving selectivity, and enhancing their delivery to cancer cells, continuous increasing in number of peptide sequences, developing a reliable and precise prediction model. In this work, we propose an efficient transformer-based framework to identify anticancer peptides for by performing accurate a reliable and precise prediction model. For this purpose, four different transformer models, namely ESM, ProtBert, BioBERT, and SciBERT are employed to detect anticancer peptides from amino acid sequences. To demonstrate the contribution of the proposed framework, extensive experiments are carried on widely-used datasets in the literature, two versions of AntiCp2, cACP-DeepGram, ACP-740. Experiment results show the usage of proposed model enhances classification accuracy when compared to the state-of-the-art studies. The proposed framework, ESM, exhibits 96.45 of accuracy for AntiCp2 dataset, 97.66 of accuracy for cACP-DeepGram dataset, and 88.51 of accuracy for ACP-740 dataset, thence determining new state-of-the-art.